Cargando…

Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users

BACKGROUND: The medial prefrontal cortex (mPFC) plays an important role in depression and addiction. Previous studies have shown alterations in glutamatergic activity in the mPFC following the administration of ketamine in patients with depression and healthy controls. However, it remains unclear wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiuxia, Tang, Jinsong, Qi, Chang, Xie, An, Liu, Jianbin, O’Neill, Joseph, Liu, Tieqiao, Hao, Wei, Liao, Yanhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343127/
https://www.ncbi.nlm.nih.gov/pubmed/35882477
http://dx.doi.org/10.1503/jpn.210179
_version_ 1784760951546839040
author Wu, Qiuxia
Tang, Jinsong
Qi, Chang
Xie, An
Liu, Jianbin
O’Neill, Joseph
Liu, Tieqiao
Hao, Wei
Liao, Yanhui
author_facet Wu, Qiuxia
Tang, Jinsong
Qi, Chang
Xie, An
Liu, Jianbin
O’Neill, Joseph
Liu, Tieqiao
Hao, Wei
Liao, Yanhui
author_sort Wu, Qiuxia
collection PubMed
description BACKGROUND: The medial prefrontal cortex (mPFC) plays an important role in depression and addiction. Previous studies have shown alterations in glutamatergic activity in the mPFC following the administration of ketamine in patients with depression and healthy controls. However, it remains unclear whether chronic, nonmedical use of ketamine affects metabolites in the mPFC. METHODS: Using proton magnetic resonance spectroscopy, we measured metabolites (glutamate and glutamine [Glx]; phosphocreatine and creatine [PCr+Cr]; myo-inositol; N-acetyl-aspartate; and glycerophosphocholine and phosphocholine [GPC+PC]) in the mPFC of chronic ketamine users (n = 20) and healthy controls (n = 43). Among ketamine users, 60% consumed ketamine once per day or more, 10% consumed it every 2 days and 30% consumed it every 3 or more days. Using analysis of covariance, we evaluated between-group differences in the ratios of Glx:PCr+Cr, myo-inositol:PCr+Cr, N-acetyl-aspartate:PCr+Cr and GPC+PC:PCr+Cr. RESULTS: Chronic ketamine users showed significantly higher Glx:PCr+Cr ratios than healthy controls (median 1.05 v. 0.95, p = 0.008). We found no significant differences in myoinositol:PCr+Cr, N-acetyl-aspartate:PCr+Cr or GPC+PC:PCr+Cr ratios between the 2 groups. We found a positive relationship between N-acetyl-aspartate:PCr+Cr and Glx:PCr+Cr ratios in the healthy control group (R = 0.345, p = 0.023), but the ketamine use group failed to show such an association (ρ = 0.197, p = 0.40). LIMITATIONS: The cross-sectional design of this study did not permit causal inferences related to higher Glx:PCr+Cr ratios and chronic ketamine use. CONCLUSION: This study provides the first evidence that chronic ketamine users have higher glutamatergic activity in the mPFC than healthy controls; this finding may provide new insights relevant to the treatment of depression with ketamine.
format Online
Article
Text
id pubmed-9343127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher CMA Impact Inc.
record_format MEDLINE/PubMed
spelling pubmed-93431272022-08-05 Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users Wu, Qiuxia Tang, Jinsong Qi, Chang Xie, An Liu, Jianbin O’Neill, Joseph Liu, Tieqiao Hao, Wei Liao, Yanhui J Psychiatry Neurosci Research Paper BACKGROUND: The medial prefrontal cortex (mPFC) plays an important role in depression and addiction. Previous studies have shown alterations in glutamatergic activity in the mPFC following the administration of ketamine in patients with depression and healthy controls. However, it remains unclear whether chronic, nonmedical use of ketamine affects metabolites in the mPFC. METHODS: Using proton magnetic resonance spectroscopy, we measured metabolites (glutamate and glutamine [Glx]; phosphocreatine and creatine [PCr+Cr]; myo-inositol; N-acetyl-aspartate; and glycerophosphocholine and phosphocholine [GPC+PC]) in the mPFC of chronic ketamine users (n = 20) and healthy controls (n = 43). Among ketamine users, 60% consumed ketamine once per day or more, 10% consumed it every 2 days and 30% consumed it every 3 or more days. Using analysis of covariance, we evaluated between-group differences in the ratios of Glx:PCr+Cr, myo-inositol:PCr+Cr, N-acetyl-aspartate:PCr+Cr and GPC+PC:PCr+Cr. RESULTS: Chronic ketamine users showed significantly higher Glx:PCr+Cr ratios than healthy controls (median 1.05 v. 0.95, p = 0.008). We found no significant differences in myoinositol:PCr+Cr, N-acetyl-aspartate:PCr+Cr or GPC+PC:PCr+Cr ratios between the 2 groups. We found a positive relationship between N-acetyl-aspartate:PCr+Cr and Glx:PCr+Cr ratios in the healthy control group (R = 0.345, p = 0.023), but the ketamine use group failed to show such an association (ρ = 0.197, p = 0.40). LIMITATIONS: The cross-sectional design of this study did not permit causal inferences related to higher Glx:PCr+Cr ratios and chronic ketamine use. CONCLUSION: This study provides the first evidence that chronic ketamine users have higher glutamatergic activity in the mPFC than healthy controls; this finding may provide new insights relevant to the treatment of depression with ketamine. CMA Impact Inc. 2022-07-26 /pmc/articles/PMC9343127/ /pubmed/35882477 http://dx.doi.org/10.1503/jpn.210179 Text en © 2022 CMA Impact Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Research Paper
Wu, Qiuxia
Tang, Jinsong
Qi, Chang
Xie, An
Liu, Jianbin
O’Neill, Joseph
Liu, Tieqiao
Hao, Wei
Liao, Yanhui
Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
title Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
title_full Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
title_fullStr Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
title_full_unstemmed Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
title_short Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
title_sort higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343127/
https://www.ncbi.nlm.nih.gov/pubmed/35882477
http://dx.doi.org/10.1503/jpn.210179
work_keys_str_mv AT wuqiuxia higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT tangjinsong higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT qichang higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT xiean higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT liujianbin higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT oneilljoseph higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT liutieqiao higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT haowei higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers
AT liaoyanhui higherglutamatergicactivityinthemedialprefrontalcortexinchronicketamineusers